To the full analysis
Surgery Partners stock: growth
SGRYSurgery Partners reported $3.31B in revenue for fiscal 2025, up 6.2% on the prior year, up 12.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
21.6%
per year from 2012 to 2025, per share 12.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
12.6%
per year from 2012 to 2025, per share 4.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 12.2% | 13.2% | 21.6% |
| Revenue per share | −7.4% | −0.2% | 12.8% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | −0.8% | 14.4% | 12.6% |
| Free cash flow per share | −18.1% | 0.8% | 4.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $260.22M | $1.92M | $41.68M |
| 2013 | $284.6M | −$9.06M | $44.93M |
| 2014 | $403.29M | −$65.9M | $12.51M |
| 2015 | $959.89M | $1.43M | $51.04M |
| 2016 | $1.15B | $9.45M | $86.13M |
| 2017 | $1.34B | −$52.99M | $91.34M |
| 2018 | $1.77B | −$205.71M | $104.8M |
| 2019 | $1.83B | −$74.8M | $55.9M |
| 2020 | $1.86B | −$116.1M | $204M |
| 2021 | $2.23B | −$70.9M | $29.5M |
| 2022 | $2.54B | −$54.6M | $78.2M |
| 2023 | $2.74B | −$11.9M | $205M |
| 2024 | $3.11B | −$168.1M | $209.7M |
| 2025 | $3.31B | −$77.9M | $195.6M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 11 Nov 2026, previously Weak
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.